Why Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADI.
Share this article
Corporate
Score 85
Bullish
Why Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADI
Mar 29, 2026 20:54 UTC
RCKT, XLV, IBB
Short term
Related Articles
Score 85
Bullish
Palantir Technologies Just Banked a Blockbuster Week. 3 Important Developments Every Shareholder Should Know.
Mar 29, 22:22
Score 65
Bullish
How Datavault AI (DVLT) Reached Its First Profitable Quarter and Set a 2026 Growth Target
Mar 29, 20:53
Score 65
Bullish
Why Vertical Aerospace (EVTL) Is Expanding Its Valo Supplier Network Ahead of Certification
Mar 29, 20:52
Score 45
Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab
Mar 29, 20:50
Stay Ahead of the Markets
Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.